Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;21(7):1737-1740.
doi: 10.1016/j.jtha.2023.03.016. Epub 2023 Mar 25.

Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets

Jecko Thachil  1 , Jean M Connors  2 , Johnny Mahlangu  3 , Michelle Sholzberg  4
Affiliations
Free article
Review

Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets

Jecko Thachil et al. J Thromb Haemost. 2023 Jul.
Free article

Abstract

Hemophilia is classified into mild, moderate, and severe based on coagulation factor activity levels. Factor replacement and prophylaxis regimens in persons with hemophilia have helped to reduce bleeding and its related complications. With several newer treatments, some already approved and others soon to be, there may be a need to consider health-related quality of life in addition to bleed prevention as the goals of providing comprehensive care to persons with hemophilia. In this article, we discussed the reasons why such an approach may be relevant and call for the International Society of Thrombosis and Haemostasis to revisit the current classification of hemophilia.

Keywords: bleeding; classification; hemophilia; symptoms.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interests J.T. received honoraria from Roche, Octapharma, Takeda, Grifols, Novo Nordisk, and Sobi pharmaceuticals. J.M. received grant/research support from Biomarin, Norvatis, Novo Nordisk, Pfizer, Roche, Sanofi, Spark, UniQure; was a consultant/on the scientific board for Biomarin, Novo Nordisk, Roche, Takeda, Sanofi, and Spark; and participated in the Speaker bureau of ISTH, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda, and WFH. J.C. and M.S. have no competing interests to disclose.

Comment in

LinkOut - more resources